These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

145 related articles for article (PubMed ID: 34993032)

  • 41. Hand-foot syndrome (hand-foot skin reaction, palmar-plantar erythrodysesthesia): focus on sorafenib and sunitinib.
    Lipworth AD; Robert C; Zhu AX
    Oncology; 2009; 77(5):257-71. PubMed ID: 19923864
    [TBL] [Abstract][Full Text] [Related]  

  • 42. Capecitabine-Induced Genital Hand-Foot Syndrome Treated With Topical Tacrolimus.
    Chan BL; Wang T
    Cureus; 2024 Apr; 16(4):e57570. PubMed ID: 38707169
    [TBL] [Abstract][Full Text] [Related]  

  • 43. Chemotherapy-associated palmar-plantar erythrodysesthesia syndrome.
    Lokich JJ; Moore C
    Ann Intern Med; 1984 Dec; 101(6):798-9. PubMed ID: 6497196
    [No Abstract]   [Full Text] [Related]  

  • 44. Oleosomes Encapsulating Sildenafil Citrate as Potential Topical Nanotherapy for Palmar Plantar Erythrodysesthesia with High Ex vivo Permeation and Deposition.
    Abdelalim LR; Elnaggar YSR; Abdallah OY
    AAPS PharmSciTech; 2020 Nov; 21(8):310. PubMed ID: 33164131
    [TBL] [Abstract][Full Text] [Related]  

  • 45. Reduced incidence of severe palmar-plantar erythrodysesthesia and mucositis in a prospective multicenter phase II trial with pegylated liposomal doxorubicin at 40 mg/m2 every 4 weeks in previously treated patients with metastatic breast cancer.
    Al-Batran SE; Meerpohl HG; von Minckwitz G; Atmaca A; Kleeberg U; Harbeck N; Lerbs W; Hecker D; Sehouli J; Knuth A; Jager E
    Oncology; 2006; 70(2):141-6. PubMed ID: 16645327
    [TBL] [Abstract][Full Text] [Related]  

  • 46. Treatment of palmar-plantar erythrodysesthesia (PPE) with topical sildenafil: a pilot study.
    Meadows KL; Rushing C; Honeycutt W; Latta K; Howard L; Arrowood CA; Niedzwiecki D; Hurwitz HI
    Support Care Cancer; 2015 May; 23(5):1311-9. PubMed ID: 25341548
    [TBL] [Abstract][Full Text] [Related]  

  • 47. Docetaxel-induced Hand and Foot Syndrome in a Patient with Metastatic Breast Carcinoma.
    Gurumurthi R; Nimmagadda RB; Mohan S
    Indian J Dermatol; 2013 Sep; 58(5):380-2. PubMed ID: 24082184
    [TBL] [Abstract][Full Text] [Related]  

  • 48. Palmar-plantar erythrodysesthesia associated with scrotal and penile involvement with capecitabine.
    Sapp CM; DeSimone P
    Clin Colorectal Cancer; 2007 Jan; 6(5):382-5. PubMed ID: 17311704
    [TBL] [Abstract][Full Text] [Related]  

  • 49. Hand foot syndrome associated with standard dose cytarabine.
    Sharma A; Baghmar S
    Indian J Med Paediatr Oncol; 2013 Oct; 34(4):333. PubMed ID: 24604970
    [TBL] [Abstract][Full Text] [Related]  

  • 50. A variant of the chemotherapy-associated erythrodysesthesia syndrome related to high-dose cyclophosphamide.
    Matsuyama JR; Kwok KK
    DICP; 1989 Oct; 23(10):776, 778-9. PubMed ID: 2815854
    [TBL] [Abstract][Full Text] [Related]  

  • 51. Palmar-plantar erythrodysesthesia in lupus during pregnancy.
    Yin H; Yang S; Zheng J; Zhou M; Liu Y; Lu L
    QJM; 2022 Jun; 115(6):417-419. PubMed ID: 35294036
    [No Abstract]   [Full Text] [Related]  

  • 52. Efficient prevention strategy against the development of a palmar-plantar erythrodysesthesia during chemotherapy.
    Lademann J; Martschick A; Kluschke F; Richter H; Fluhr JW; Patzelt A; Jung S; Chekerov R; Darvin ME; Haas N; Sterry W; Zastrow L; Sehouli J
    Skin Pharmacol Physiol; 2014; 27(2):66-70. PubMed ID: 23969763
    [TBL] [Abstract][Full Text] [Related]  

  • 53. Prevention strategies in palmar-plantar erythrodysesthesia onset: the role of regional cooling.
    Mangili G; Petrone M; Gentile C; De Marzi P; Viganò R; Rabaiotti E
    Gynecol Oncol; 2008 Feb; 108(2):332-5. PubMed ID: 18083217
    [TBL] [Abstract][Full Text] [Related]  

  • 54. Palmar-plantar erythrodysesthesia syndrome following treatment with high-dose methotrexate or high-dose cytarabine.
    Karol SE; Yang W; Smith C; Cheng C; Stewart CF; Baker SD; Sandlund JT; Rubnitz JE; Bishop MW; Pappo AS; Jeha S; Pui CH; Relling MV
    Cancer; 2017 Sep; 123(18):3602-3608. PubMed ID: 28493546
    [TBL] [Abstract][Full Text] [Related]  

  • 55. Palmar-plantar erythrodysesthesia.
    Wilkes GM; Doyle D
    Clin J Oncol Nurs; 2005 Feb; 9(1):103-6. PubMed ID: 15751504
    [No Abstract]   [Full Text] [Related]  

  • 56. The use of cod liver oil by patients receiving pegylated liposomal doxorubicin is associated with a lack of severe palmar-plantar erythrodysesthesia.
    Kanis M; Kesterson JP; Lele S
    Eur J Gynaecol Oncol; 2009; 30(4):387-8. PubMed ID: 19761128
    [TBL] [Abstract][Full Text] [Related]  

  • 57. Therapeutic Apheresis, Circulating PLD, and Mucocutaneous Toxicity: Our Clinical Experience through Four Years.
    Filip S; Kubeček O; Špaček J; Lánská M; Bláha M
    Pharmaceutics; 2020 Sep; 12(10):. PubMed ID: 33008072
    [TBL] [Abstract][Full Text] [Related]  

  • 58. Penile involvement with hand-foot syndrome.
    Sorscher SM
    Am J Clin Dermatol; 2004; 5(3):209-10. PubMed ID: 15186201
    [TBL] [Abstract][Full Text] [Related]  

  • 59. Is pyridoxine helpful in preventing palmar-plantar erythrodysesthesia associated with capecitabine?
    Jeung HC; Chung HC
    Asia Pac J Clin Oncol; 2010 Sep; 6(3):141-3. PubMed ID: 20887492
    [No Abstract]   [Full Text] [Related]  

  • 60. Docetaxel induced severe palmar plantar erythrodysesthesia.
    Kharmoum S; Errihani H
    Pan Afr Med J; 2018; 30():70. PubMed ID: 30344854
    [No Abstract]   [Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 8.